As of Wednesday close, Sarepta Therapeutics Inc.’s (NASDAQ:SRPT) stock was down -$0.11, moving down -0.10 percent to $113.97. The average number of shares traded per day over the past five days has been 1,327,500 shares. 5 times new highs have been achieved over the past 5 days, with a $10.61 gain in that time frame. In the last twenty days, the average volume was 1,064,380, while in the previous 50 days, it was 1,137,082.
Since last month, SRPT stock rose 6.89%. Shares of the company fell to $100.72 on 08/08/23, the lowest level in the past month. A 52-week high of $159.89 was reached on 05/15/23 after having rallying from a 52-week low of $100.15. Since the beginning of this year, SRPT’s stock price has dropped by -12.05% or -$15.61, and marked a new high 10 times. However, the stock has declined by -28.72% since its 52-week high.
SRPT stock investors should be aware that Sarepta Therapeutics Inc. (SRPT) stock had its last reported insider trading activity 3 days ago on Aug 14. Chambers Michael Andrew, the Director of the company, purchased of 9,979 shares for $109.47 on Aug 14. It resulted in a $1,092,429 investment by the insider. Chambers Michael Andrew added 23,686 shares at an average price of $108.05 on Aug 11. The insider now owns 237,017 shares following the transaction. On Aug 10, Director Chambers Michael Andrew bought 34,867 shares at $106.15 apiece. The transaction was valued at $3,701,067.
Valuation Metrics
The stock’s beta is 0.94. Besides these, the trailing price-to-sales (P/S) ratio of 10.40, the price-to-book (PB) ratio of 13.65.
Financial Health
In the three months ended June 29, Sarepta Therapeutics Inc.’s quick ratio stood at 4.50, while its current ratio was 5.00, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 1.67, and the total debt-to-equity ratio was 1.67. On the profitability front, the trailing twelve-month gross margin is 86.10% percent. In the year ended June 29, EBITDA margin amounted to -50.97%, whereas operating margins totaled -92.00%. Based on annual data, SRPT earned $793.02 million in gross profit and brought in $933.01 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -35.10%. Return on equity (ROE) for the past 12 months was -159.90%.
In Sarepta Therapeutics Inc.’s quarter-end financial report for June 29, it reported total debt of $1.24 billion against cash and short-term investments of $1.01 billion. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. SRPT’s revenue rose 10.62% to $253.5 million during the quarter, while net income inched up to $261.24 million. While analysts expected Sarepta Therapeutics Inc. to report -$1.78 quarterly earnings, the actual figure was -$0.27 per share, beating the consensus estimate by 84.80%. During the quarter, the company generated -$134.32 million in EBITDA. The liabilities of Sarepta Therapeutics Inc. were 2.38 billion at the end of its most recent quarter ended June 29, and its total debt was $1.38 billion. The value of shareholders’ equity is $93.28 million.
Technical Picture
This quick technical analysis looks at Sarepta Therapeutics Inc.’s (SRPT) price momentum. With a historical volatility rate of 31.01%, the RSI 9-day stood at 70.89% on 16 August.
With respect to its five-day moving average, the current Sarepta Therapeutics Inc. price is up by +10.27% percent or $10.61. At present, SRPT shares trade +7.61% above its 20-day simple moving average and -11.73% percent below its 100-day simple moving average. However, the stock is currently trading approximately -9.67% below its SMA50 and -0.30% below its SMA200.
Stochastic coefficient K was 92.13% and Stochastic coefficient D was 77.18%, while ATR was 3.40. Given the Stochastic reading of 93.37% for the 14-day period, the RSI (14) reading has been calculated as 61.13%. As of today, the MACD Oscillator reading stands at 5.85, while the 14-day reading stands at 5.93.
Analyst Ratings
Sarepta Therapeutics Inc. downgraded its rating on Sarepta Therapeutics Inc. (NASDAQ: SRPT) to an In-line in a note to investors on June 23, 2023. The analysts firm previously had an Outperform rating on the stock.Sarepta Therapeutics Inc. (SRPT) has been rated Overweight by analysts. According to 0 brokerage firms, SRPT is a sell, and 4 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 2 analysts rate Sarepta Therapeutics Inc. stock as buy, with 14 recommending it as overweight.
With a median target price of $180.00, the current consensus forecast for the stock is $139.00 – $223.00. Based on these forecasts, analysts predict Sarepta Therapeutics Inc. (SRPT) will achieve an average price target of $179.21.
